Precision Biosciences Inc
NASDAQ:DTIL
Earnings Announcements
Precision Biosciences Reports Q1 Results
Published: 05/09/2022 13:45 GMT
Precision Biosciences Inc (DTIL) - Precision Biosciences Reports First Quarter 2022 Financial Results and Provides Business Update.
Precision Biosciences - Expects Existing Cash, Operational Receipts and Available Credit to Fund Operating Expenses and Capex Requirements Into Mid-2023.
Total Revenues for Quarter Ended March 31, 2022 Were $3.3 Million, As Compared to $16.3 Million for Same Period in 2021.
Q1 Loss per Share $0.46.
Q1 Earnings per Share View $-0.54, Revenue View $7.7 Million -- Refinitiv Ibes Data (analyst estimates).
Precision Biosciences - Expects Existing Cash, Operational Receipts and Available Credit to Fund Operating Expenses and Capex Requirements Into Mid-2023.
Total Revenues for Quarter Ended March 31, 2022 Were $3.3 Million, As Compared to $16.3 Million for Same Period in 2021.
Q1 Loss per Share $0.46.
Q1 Earnings per Share View $-0.54, Revenue View $7.7 Million -- Refinitiv Ibes Data (analyst estimates).
Revenue is expected to be $5.97 Million
Adjusted EPS is expected to be -$0.44
Next Quarter Revenue Guidance is expected to be $6.07 Million
Next Quarter EPS Guidance is expected to be -$0.46
More details on our Analysts Page.
Adjusted EPS is expected to be -$0.44
Next Quarter Revenue Guidance is expected to be $6.07 Million
Next Quarter EPS Guidance is expected to be -$0.46
More details on our Analysts Page.